Dr. Schultze-Florey studied Human medicine in Hanover, Lausanne and Toulouse. In 2009, she obtained her license to practice medicine after her state examination and began a residency at the MHH Children's Hospital in the Common Trunk Program, a rotation program for pediatric residents. Her doctorate in 2010 under Prof. Dr. Dr. Christoph Klein (Department of Pediatric Hematology and Oncology) at the MHH and Harvard Medical School in Boston, USA, focused on the molecular pathological characterization of an immunodeficiency, severe congenital neutropenia.
After completing the common trunk program, Ms. Schultze-Florey joined the Department of Pediatric Hematology and Oncology as a resident in 2012. In addition to her clinical work, she began working as a study physician in the BMBF-funded "Integrated Research and Treatment Center Transplantation (IFB-Tx)" in Prof. Dr. Britta Maecker-Kolhoff's working group for the Allo-EBT study. This study deals with new cell-based therapeutic approaches for refractory PTLD (post-transplant lymphoproliferative disease).
She completed her specialist training in pediatrics and adolescent medicine in 2016 and is now training to become a pediatric hematologist/oncologist. In 2017/2018, she supervised her own start-up project at the IFB-Tx on the topic of biomarkers as predictive values for PTLD. Since 2019, Dr. Schultze-Florey has been head of the prospective multicenter follow-up study EB-VISI (Epstein-Barr virus specific immunity), funded by the Tx Center of the MHH. She is also a scholarship holder of the Ellen Schmidt Program for the promotion of habilitation.
Dr. Schultze-Florey is a member of the Society for Pediatric Hematology and Oncology (GPOH) and the German Society for Pediatric and Adolescent Medicine (DGKJ).